^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SORT1 expression

    i
    Other names: SORT1, Sortilin 1, Neurotensin Receptor 3, 100 KDa NT Receptor, Glycoprotein 95, Sortilin, Gp95, NTR3, NT3, LDLCQ6
    Entrez ID:
    6272
    Related biomarkers:
    Expression
    Mutation
    over1year
    Elevated sortilin expression discriminates functional from non-functional neuroendocrine tumors and enables therapeutic targeting. (PubMed, Front Endocrinol (Lausanne))
    Here, we demonstrate that the expression of sortilin, a widely expressed transmembrane receptor involved in intracellular protein sorting, is significantly increased in functional compared to non-functional NETs and thus can be used as a biomarker for functional NETs. Furthermore, using a cell line model of functional NETs, as well as organoids, we demonstrate that inhibition of sortilin reduces cellular serotonin concentrations and may therefore serve as a novel therapeutic target to treat patients with carcinoid syndrome.
    Journal
    |
    SORT1 (Sortilin 1)
    |
    SORT1 expression
    over2years
    TH1902 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=70, Recruiting, Theratechnologies | Active, not recruiting --> Recruiting
    Enrollment open • Metastases
    |
    CD4 (CD4 Molecule)
    |
    SORT1 expression
    |
    sudocetaxel zendusortide (TH 1902)
    over2years
    TH1902 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=70, Active, not recruiting, Theratechnologies | Trial completion date: Mar 2023 --> Dec 2024 | Trial primary completion date: Mar 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    CD4 (CD4 Molecule)
    |
    SORT1 expression
    |
    sudocetaxel zendusortide (TH 1902)
    over2years
    Influence of EGF and pro-NGF on EGFR/SORTILIN interaction and clinical impact in head and neck squamous cell carcinoma. (PubMed, Front Oncol)
    These results therefore suggest a regulatory role for Sortilin in the degradation or renewal of EGFR on the membrane. It would be interesting in future work to show the intracellular fate of EGFR and the role of (pro)neurotrophins in these mechanisms.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • SORT1 (Sortilin 1)
    |
    EGFR overexpression • SORT1 expression
    over2years
    The Membrane Protein Sortilin Is a Potential Biomarker and Target for Glioblastoma. (PubMed, Cancers (Basel))
    Interestingly, targeting sortilin with the orally bioavailable small molecule inhibitor AF38469 resulted in decreased GBM invasiveness, but cancer cell proliferation was not affected, showing that sortilin is targetable in GBM. Together, these data suggest the clinical relevance for sortilin in GBM and support further investigation of GBM as a clinical biomarker and therapeutic target.
    Journal
    |
    SORT1 (Sortilin 1)
    |
    SORT1 expression
    over2years
    Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study. (ASCO 2023)
    TH1902 is a first-in-class PDC targeting SORT1, that consists of 2 molecules of docetaxel attached to the TH19P01 peptide via a cleavable succinyl linker. Although biological activity has been observed, the optimal dosing regimen of TH1902 is currently under evaluation. Clinical trial information: NCT04706962.
    Clinical • P1 data • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • SORT1 (Sortilin 1)
    |
    SORT1 expression
    |
    docetaxel • sudocetaxel zendusortide (TH 1902)
    over2years
    Differential expression of a novel transport receptor, SORT1 (sortilin), in cancer versus healthy tissues that can be utilized for targeted delivery of anti-cancer drugs (AACR 2023)
    SORT1 is currently being studied as a cancer target in a first-in-human (FIH) study of a peptide-drug conjugate (clinicaltrial.gov: NCT04706962). These results suggest that SORT1 is highly expressed in multiple tumors and is a promising target for the delivery and internalization of cancer therapeutic agents.
    Clinical
    |
    SORT1 (Sortilin 1)
    |
    SORT1 expression
    almost3years
    TH1902 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=70, Active, not recruiting, Theratechnologies | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    CD4 (CD4 Molecule)
    |
    SORT1 expression
    |
    sudocetaxel zendusortide (TH 1902)